2023 The Final Countdown, page-1345

To be honest I think the focus for MSBs board is approval, not the share price. The share price is our focus - which it shouldn't be until after approval, or non approval unless individuals feel they need to jump ship now. Which is neither the right or wrong thing for the individual if they feel they are making an educated decision.

Nothing so far has suggested msb would do such a thing, nor do we have reason to think Krause would. And as you can see it hasn't really led to much of a rally.

I'm sure there are other ways MSB could pump that would be considerably more effective. I mean just look to the methods of other biotech.